These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 39006524)

  • 1. Biomarkers of immunotherapy in glioblastoma.
    Savage WM; Yeary MD; Tang AJ; Sperring CP; Argenziano MG; Adapa AR; Yoh N; Canoll P; Bruce JN
    Neurooncol Pract; 2024 Aug; 11(4):383-394. PubMed ID: 39006524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.
    Neagu MR; Reardon DA
    Curr Treat Options Oncol; 2015 Nov; 16(11):54. PubMed ID: 26454859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Biomarkers for Immunotherapy in Glioblastoma.
    Mensali N; Inderberg EM
    Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
    Medikonda R; Pant A; Lim M
    Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Barriers to overcoming immunotherapy resistance in glioblastoma.
    Gillette JS; Wang EJ; Dowd RS; Toms SA
    Front Med (Lausanne); 2023; 10():1175507. PubMed ID: 37275361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigen discovery and applications in glioblastoma: An immunotherapy perspective.
    Wang C; Yu M; Zhang W
    Cancer Lett; 2022 Dec; 550():215945. PubMed ID: 36216148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
    Yeo AT; Charest A
    J Cell Biochem; 2017 Sep; 118(9):2516-2527. PubMed ID: 28230277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in immunotherapy for glioblastoma multiforme.
    Mahmoud AB; Ajina R; Aref S; Darwish M; Alsayb M; Taher M; AlSharif SA; Hashem AM; Alkayyal AA
    Front Immunol; 2022; 13():944452. PubMed ID: 36311781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for glioblastoma: the promise of combination strategies.
    Bausart M; Préat V; Malfanti A
    J Exp Clin Cancer Res; 2022 Jan; 41(1):35. PubMed ID: 35078492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
    Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
    J Big Data; 2022; 9(1):92. PubMed ID: 35855914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
    Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging patents in the therapeutic areas of glioma and glioblastoma.
    Harris M; Svensson F; Kopanitsa L; Ladds G; Bailey D
    Expert Opin Ther Pat; 2018 Jul; 28(7):573-590. PubMed ID: 29950117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy and Epigenetic Pathway Modulation in Glioblastoma Multiforme.
    Chin C; Lunking ES; de la Fuente M; Ayad NG
    Front Oncol; 2018; 8():521. PubMed ID: 30483476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.
    Zhai L; Dey M; Lauing KL; Gritsina G; Kaur R; Lukas RV; Nicholas MK; Rademaker AW; Dostal CR; McCusker RH; Raizer JJ; Parsa AT; Bloch O; Wainwright DA
    J Clin Neurosci; 2015 Dec; 22(12):1964-8. PubMed ID: 26279502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.
    Sener U; Ruff MW; Campian JL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Status and Challenges of Vaccination Therapy for Glioblastoma.
    Hosseinalizadeh H; Rahmati M; Ebrahimi A; O'Connor RS
    Mol Cancer Ther; 2023 Apr; 22(4):435-446. PubMed ID: 36779991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances and future of immunotherapy for glioblastoma.
    Kamran N; Calinescu A; Candolfi M; Chandran M; Mineharu Y; Asad AS; Koschmann C; Nunez FJ; Lowenstein PR; Castro MG
    Expert Opin Biol Ther; 2016 Oct; 16(10):1245-64. PubMed ID: 27411023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarkers for immunotherapy for treatment of glioblastoma.
    Lynes JP; Nwankwo AK; Sur HP; Sanchez VE; Sarpong KA; Ariyo OI; Dominah GA; Nduom EK
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32474411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.